Exemestane 25 mg
25 mg · 30 tablets · Exemestane 25 mg is a powerful steroidal AI for irreversible estrogen suppression — ideal for PCT, testosterone recovery, and advanced hormonal modulation with long-acting PK support.
€ 38.00
Beskrivning
Exemestane 25 mg
Varumärke: Magnus Läkemedel
Innehåll: 30 tablets | 25 mg per tablet
Pris: €38
Tillverkad i: Europa
🧪 Produktöversikt
Exemestane 25 mg is a third-generation, steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme, producing sustained suppression of systemic estrogen. Widely used in hormonal modulation and post-cycle therapy (PCT) research, it is particularly effective for testosterone-boosting protocols and estrogen-dependent tumor investigations.
A single 25 mg dose lowers estradiol by 60–80% within 12 hours and sustains suppression for up to 48 hours due to its ~24–27 hour half-life. Studies confirm its effectiveness in raising LH, FSH, and modestly increasing endogenous testosterone without altering adrenal androgens. This compound is listed on WADA’s S4 prohibited list for hormone modulators.
✅ Viktiga forskningsresultat
Irreversible aromatase blockade:
Covalently deactivates CYP19, maintaining estrogen suppression post-clearance [ScienceDirect]
24-hour pharmacokinetics:
Half-life of 24–27 hours ensures stable once-daily dosing in long-term hormonal protocols [PubMed]
↑ Testosterone-to-estradiol ratio:
25 mg/day improved T:E ratios in male models without affecting DHEA/androstenedione [FDA data]
Bone & lipid impact (chronic use):
Long-term data show ↓ BMD and HDL↓ / LDL↑ — relevant for extended-duration studies [PubMed, PMC]
Shelf-stable & lab-friendly:
Film-coated tablets remain potent at ≤25 °C without refrigeration [ICH Stability, MSDS]
🧬 Föreslagna laboratorieapplikationer
-
Irreversible aromatase inhibition and estrogen-suppression modeling
-
Testosterone enhancement in male hypogonadism models
-
PCT studies for anabolic-recovery protocols
-
LH/FSH modulation research
-
Tamoxifen-resistant estrogen-tumor studies
📊 Tekniska specifikationer
| Fält | Uppgifter |
|---|---|
| Kemiskt namn | Exemestane (INN) |
| Kemisk formel | C<sub>20</sub>H<sub>24</sub>O<sub>2</sub> |
| Synonymer | Aromasin; FCE 24304; 6-methyleneandrosta-1,4-diene-3,17-dione |
| Molekylvikt | 296.4 g/mol |
| CAS-nummer | 107868-30-4 |
| Halveringstid | ~24–27 hours |
| Detektionsfönster | Medium-long, varies with protocol |
| Dokumenterade fördelar | ↓ E2 by 60–80%, ↑ LH/FSH, ↑ T, stable estrogen suppression |
| Huvudsakliga risker | ↓ BMD, lipid shifts, fatigue, joint pain, hot flashes |
| Total aktiv förening | 750 mg per carton (25 mg × 30 tablets) |
| Hållbarhetstid | 36 månader (tillverkarens specifikation) |
❄️ PubChem-stödda forskningsinsikter
-
Irreversible suppression of estrogen via steroidal aromatase inhibition
-
Rapid E2 reduction within 12 hours of dosing
-
Increases T:E ratio in male subjects without disturbing adrenal steroids
-
Maintains hormonal control for up to 48 hours post-dose
-
Applied in resistant ER+ tumor model studies and androgen support trials
⚠️ Dokumenterad forskning Biverkningar
-
Common: Hot-flushes, arthralgia, fatigue, insomnia
-
Long-term: Bone mineral density reduction, HDL↓/LDL↑
-
Other: Menopausal symptoms and mood variations
-
Listed under WADA S4 — prohibited in all competitive levels
🧯 Hantering & efterlevnad
Endast för forskningsändamål - Ej för human- eller veterinärmedicinsk användning
Butik på 15-25 °C, protect from light and moisture
Köpbekräftelser kvalificerad forskare status
Listad på WADA:s förbjudna lista S4 — any exposure may result in a positive test
Det finns inga recensioner ännu.
